Tumor necrosis related receptor, TR7
AssigneeSmithKline Beecham Corporation
InventorsKeith Charles Deen, Mark R. Hurle, Peter Young, Kong B. Tan
Life of this patent
Estimating the term…
Abstract
TR7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR7 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (such as inflammatory bowel disease and psoriasis), transplant rejection, graft versus host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases, cancer (such as lymphoproliferative disorders), atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.
Claims17
An isolated TR7 polypeptide comprising the amino acid sequence of SEQ ID NO:2.
A composition comprising an isolated TR7 polypeptide, the isolated TR7 polypeptide comprising the amino acid sequence of SEQ ID NO:2.
An isolated TR7 polypeptide comprising the amino acid sequence of SEQ ID NO:4.
A composition comprising an isolated TR7 polypeptide, the isolated TR7 polypeptide comprising the amino acid sequence of SEQ ID NO:4.
An isolated TR7 polypeptide comprising at least 20 contiguous amino acids of the amino acid sequence of SEQ ID NO:6.
A composition comprising an isolated TR7 polypeptide, the isolated TR7 polypeptide comprising at least 20 contiguous amino acids of the amino acid sequence of SEQ ID NO:6, wherein the polypeptide has at least one cysteine-rich motif characteristic of an extracellular domain of Tumor Necrosis Factor Receptors.
Dependencies are inferred from the claim text.